Is Nivolumab an imported drug or a domestic drug?

Nivolumab (Nivolumab) is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). It was developed by Bristol Myers Squibb. The original drug was approved by the National Medical Products Administration in 2018 and was marketed in China. The trade name is Opdivo and it is an imported drug. This is the first monoclonal antibody drug targeting PD-1 approved in China, and also the first immuno-oncology drug in China for the treatment of advanced gastric cancer. Nivolumab has been approved for many cancer types and stages, in some cases as monotherapy and in some cases in combination with ipilimumab, another immunotherapy.